1. Home
  2. ENTX vs VWAV Comparison

ENTX vs VWAV Comparison

Compare ENTX & VWAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$2.08

Market Cap

142.0M

Sector

Health Care

ML Signal

HOLD

VWAV

VisionWave Holdings Inc.

N/A

Current Price

$8.60

Market Cap

152.5M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ENTX
VWAV
Founded
2010
2024
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
142.0M
152.5M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ENTX
VWAV
Price
$2.08
$8.60
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
77.7K
175.1K
Earning Date
11-14-2025
11-19-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$124,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
25.25
N/A
52 Week Low
$1.50
$2.06
52 Week High
$3.22
$18.41

Technical Indicators

Market Signals
Indicator
ENTX
VWAV
Relative Strength Index (RSI) 32.95 N/A
Support Level $2.07 N/A
Resistance Level $2.22 N/A
Average True Range (ATR) 0.15 0.00
MACD -0.02 0.00
Stochastic Oscillator 5.42 0.00

Price Performance

Historical Comparison
ENTX
VWAV

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About VWAV VisionWave Holdings Inc.

VisionWave Holdings Inc is engaged in revolutionizing defense capabilities by integrating artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. Its innovations range from high-resolution radars and vision systems to radio frequency (RF) sensing technologies are seeking to redefine operational efficiency and precision for military and homeland security applications globally.

Share on Social Networks: